Conflicts of Interest – AZ

• Oxford University – Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. ^{^07}
  • Oxford University could also collect a big windfall, as it holds a 5.4% stake directly. It also owns further stakes through the university’s spin-out holding company, Oxford Sciences Innovation (OSI). ^{^08}
• Alexander D Douglas – ADD reports grants and personal fees from AstraZeneca, outside of the submitted work. ^{^07}
• ^{Pedro M Folegatti – Consultant to Vaccitech during the conduct of the study. ^07}
• Adam Finn – Member of the JCVI
  • Chair of the WHO European Technical Advisory Group of Experts.
  • Grants from Pfizer
  • Grants from GlaxoSmithKline
  • Grants from Sanofi
  • Grants from Merck Sharp & Dohme
  • Grants from Valneva. ^{^07}
• Sarah C Gilbert – co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). ^{^09}
  • Prof Sarah Gilbert, scientist who led the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US.
  • Gilbert owns 5.2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for MERS, hepatitis B, and a range of cancers. ^{^10}
• Catherine M Green – Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
  • During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine. ^{^11}
  • Reports personal fees from the Duke Human Vaccine Institute, outside of the submitted work. ^{^12}
• Hill AVS – AVSH reports personal fees from Vaccitech, outside of the submitted work, and has a patent on ChAdOx1 licensed to Vaccitech (PCT/GB2012/000467), will from royalty income to the University of Oxford from sales of this vaccine by AstraZeneca and sublicensees. ^{^09 Adrian Hill’s stakes could be worth £22m. ^13}
• Andrew J Pollard; Oxford COVID Vaccine Trial Group – Chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI)
  • Member of WHO’s SAGE
  • National Institute for Health Research (NIHR) Senior Investigator. ^{^09}
• Matthew D Snape – Grants from NIHR and non-financial support from AstraZeneca, during the conduct of the study
  • Grants from Janssen
  • Grants from GlaxoSmithKline
  • Grants from Medimmune
  • Grants from Novavax
  • Grants from MCM
  • Grants and non-financial support from Pfizer. ^{^09}
•  Johan Vekemans – employee of AstraZeneca. ^{^09}
•  Tonya L Villafana – named as an inventor on a patent application covering this SARS-CoV-2 vaccine.
  • A consultant to Vaccitech for an unrelated project, during the conduct of the study.
  • Employee of AstraZeneca. ^{^09}

ANDREW POLLARD Prof

• Lead developer of the Bexsero meningococcal B vaccine ^{^14}, previously owned by Novartis and now owned by GSK.
• Chair of The Joint Committee on Vaccination & Immunisation (JCVI) ^{^15}, who advises UK health departments on immunisation.
• Director of the Oxford Vaccine Group (OVG) ^{^16}, which received funding from vaccine manufacturers for their trials ^{^17}.
• Professor of Paediatric Infection and Immunity at the University of Oxford, which has significant financial influence from Vaccine Manufacturing and Innovation Centre UK ^{^18.}
• Was chair of the European Medicines Agency, Scientific Advisory Group of Vaccines (ASAGV) ^{^19}, whose main stakeholders are pharmaceutical industries ^{^20}
• Chaired the UK’s National Institute for Health and care Excellence (NICE) meningitis guidelines development group ^{^21}
• Developer in AstraZeneca Oxford COVID-19 Vaccine ^{^22.}

Declared Competing Interests in the AstraZeneca Trials Analysis

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.

• Oxford University – Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. ^{^09}
  • Oxford University could also collect a big windfall, as it holds a 5.4% stake directly. It also owns further stakes through the university’s spin-out holding company, Oxford Sciences Innovation (OSI). ^{^13}

• Alexander D Douglas – reports grants and personal fees from AstraZeneca, outside of the submitted work. ^{^09}

• Pedro M Folegatti – Consultant to Vaccitech during the conduct of the study. ^{^09}

• Adam Finn – Member of the JCVI
  • Chair of the WHO European Technical Advisory Group of Experts.
  • Grants from Pfizer
  • Grants from GlaxoSmithKline
  • Grants from Sanofi
  • Grants from Merck Sharp & Dohme
  • Grants from Valneva. ^{^09}

• Sarah C Gilbert – co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). ^{^09}
  • Prof Sarah Gilbert, scientist who led the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US.
  • Gilbert owns 5.2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for MERS, hepatitis B, and a range of cancers. ^{^23}

• Catherine M Green – Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
  • During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine. ^{^24}
  • Reports personal fees from the Duke Human Vaccine Institute, outside of the submitted work. ^{^25}

• Hill AVS – AVSH reports personal fees from Vaccitech, outside of the submitted work, and has a patent on ChAdOx1 licensed to Vaccitech (PCT/GB2012/000467), will from royalty income to the University of Oxford from sales of this vaccine by AstraZeneca and sublicensees. ^{^09} Adrian Hill’s stakes could be worth £22m. ^{^13}

• Andrew J Pollard; Oxford COVID Vaccine Trial Group – Chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI)
  • Member of WHO’s SAGE
  • National Institute for Health Research (NIHR) Senior Investigator. ^{^09}

• Matthew D Snape – Grants from NIHR and non-financial support from AstraZeneca, during the conduct of the study
  • Grants from Janssen
  • Grants from GlaxoSmithKline
  • Grants from Medimmune
  • Grants from Novavax
  • Grants from MCM
  • Grants and non-financial support from Pfizer. ^{^09}

•  Johan Vekemans – employee of AstraZeneca. ^{^09}

•  Tonya L Villafana – named as an inventor on a patent application covering this SARS-CoV-2 vaccine.
  • A consultant to Vaccitech for an unrelated project, during the conduct of the study.
  • Employee of AstraZeneca. ^{^09}